相关实验视频
Updated: Jul 16, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
血管负担和粉样β病理之间的相互作用对陶积累的轨迹
Emma M Coomans1,2,3,4, Danielle van Westen3, Alexa Pichet Binette3
1Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, 1081HV Amsterdam, The Netherlands.
Brain : a journal of neurology
|September 18, 2023
概括
脑血管病理,特别是微血,与粉样蛋白-β相互作用,以加速阿尔茨海默氏症早期的陶积累. 这表明,准微型血液可能会减缓疾病的进展. (35个单词) 的意思.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 医疗成像医学成像
背景情况:
- 大脑血管病理经常与阿尔茨海默氏病 (AD) 病理学同时发生.
- 血管负担对AD病理进展的贡献仍然不清楚.
- 了解这些相互作用对于开发有效的AD治疗至关重要.
研究的目的:
- 为了研究血管负担和粉样β (Aβ) 病理之间的相互作用.
- 评估对基线tau纠负荷和纵向tau积累的影响.
- 用尸检数据验证体内发现.
主要方法:
- 来自瑞典BioFINDER-2研究的1229名参与者接受了基线和纵向tau-PET成像.
- 血管特征包括微型血液,白质病变,中风事件和心血管风险评分.
- 1610例尸检病例被分析为大脑粉样血管病变,白质稀缺和心脏病发作.
主要成果:
- 在没有认知障碍的个体中,微血液与Aβ病理有显著的相互作用,增加了基线tau负载和纵向tau积累.
- 与中风相关的事件显示,在纵向测量中与Aβ有显著的负面相互作用.
- 尸检数据复制了脑粉样血管病变和心脏病发作的体内发现.
结论:
- 脑血管病理,在Aβ病理的存在下,在AD早期修改了tau的积累.
- 微型血液和Aβ病理的同时发生与加速的陶积累有关.
- 准微型血液可能提供一种治疗策略,以减轻阿尔茨海默病的陶积累.
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212

